Premium
Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women?
Author(s) -
Bianchi Diana W.,
Oepkes Dick,
Ghidini Alessandro
Publication year - 2014
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.4229
Subject(s) - aneuploidy , medicine , prenatal diagnosis , down syndrome , fetus , obstetrics , test (biology) , pregnancy , genetic testing , dna testing , diagnostic test , cell free fetal dna , prenatal screening , gynecology , pediatrics , chromosome , genetics , biology , psychiatry , paleontology , gene
What's already known about this topic? Noninvasive DNA testing (NIDT) is recommended in many developed countries as an option for pregnant women who have already been determined to be at high risk for fetal aneuploidy. Over 2 years of clinical experience has been accumulated with offering NIDT as an advanced screen for fetal autosomal aneuploidy. At the present time, most testing is being performed by commercial organizations.What does this study add? This study provides a written transcript to accompany an oral debate that was presented at the 17 th International Conference on Prenatal Diagnosis and Therapy in Lisbon, Portugal, on 3 June 2013. The debaters, who are both experts in maternal–fetal medicine, consider the benefits and limitations of offering NIDT to all pregnant women regardless of their a priori risk of having a fetus with a chromosome abnormality.